Transcriptomics reveals new regulatory mechanisms involved in benralizumab response

[EN] Benralizumab, a monoclonal antibody targeting IL5RA, significantly improves asthma symptoms and quality of life in severe asthmatic patients. However, understanding the factors influencing treatment response remains a challenge. In this prospective observational study, we analyzed transcriptomi...

Descripción completa

Detalles Bibliográficos
Autores: Estravís Sastre, Miguel, Pérez Pazos, Jacqueline, Moreno‐Jimenez, Emma, Triviño, Juan Carlos, García Sánchez, María Asunción, Gómez‐García, Manuel, Morgado, Natalia, Ramos González, Jacinto, Gil Melcón, María, Martín García, Cristina, Muñoz Bellido, Francisco Javier, Sanz Lozano, Catalina Sofía, Isidoro García, María, Dávila González, Ignacio Jesús
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Salamanca (USAL)
Repositorio:GREDOS. Repositorio Institucional de la Universidad de Salamanca
OAI Identifier:oai:gredos.usal.es:10366/158780
Acceso en línea:http://hdl.handle.net/10366/158780
Access Level:acceso abierto
Palabra clave:Benralizumab
Transcriptomics
Asthma biomarkers
CRSwNP
N-ERD
Exacerbated respiratory disease
Genetics
Allergy and Immunology
3207.01 Alergias
2409 Genética
alergia e inmunología
genética
Descripción
Sumario:[EN] Benralizumab, a monoclonal antibody targeting IL5RA, significantly improves asthma symptoms and quality of life in severe asthmatic patients. However, understanding the factors influencing treatment response remains a challenge. In this prospective observational study, we analyzed transcriptomic changes in peripheral whole blood samples from 15 severe asthmatic patients treated with benralizumab for 6 months. The study included patients with two frequent comorbidities: nasal polyposis (CRSwNP) and NSAID-exacerbated respiratory disease (N-ERD)

Similares en LA Referencia